Population Pharmacokinetics of Anidulafungin in Critically Ill Patients.
S LuqueWilliam W HopeN CampilloR Muñoz-BermúdezL SorliJ Barceló-VidalE González-ColominasF Alvarez-LermaJ R MasclansM MonteroJuan Pablo HorcajadaS GrauPublished in: Antimicrobial agents and chemotherapy (2019)
A two-compartment pharmacokinetic (PK) population model of anidulafungin was fitted to PK data from 23 critically ill patients (age, 65 years [range, 28 to 81 years]; total body weight [TBW], 75 kg [range, 54 to 168 kg]). TBW was associated with clearance and incorporated into a final population PK model. Simulations suggested that patients with higher TBWs had less-extensive MIC coverage. Dosage escalation may be warranted in patients with high TBWs to ensure optimal drug exposures for treatment of Candida albicans and Candida glabrata infections.